{"id":21391,"date":"2016-05-18T11:44:09","date_gmt":"2016-05-18T10:44:09","guid":{"rendered":"http:\/\/blog.cofb.cat\/?p=21391"},"modified":"2016-05-18T11:44:09","modified_gmt":"2016-05-18T10:44:09","slug":"els-biosimilars-arriben-a-la-farmacia-que-hem-de-saber","status":"publish","type":"post","link":"https:\/\/www.cofb.org\/ca\/2016\/05\/18\/els-biosimilars-arriben-a-la-farmacia-que-hem-de-saber\/","title":{"rendered":"Els biosimilars arriben a la farm\u00e0cia, qu\u00e8 hem de saber?"},"content":{"rendered":"<p><a href=\"http:\/\/blog.cofb.cat\/wp-content\/uploads\/2016\/05\/biosimilars-COFB-mar\u00e7-2016-1.jpg\"><img fetchpriority=\"high\" decoding=\"async\" class=\" wp-image-21402 alignright\" alt=\"biosimilars-COFB-mar\u00e7-2016 (1)\" src=\"http:\/\/blog.cofb.cat\/wp-content\/uploads\/2016\/05\/biosimilars-COFB-mar\u00e7-2016-1.jpg\" width=\"298\" height=\"172\" \/><\/a>A finals del 2015 es va comercialitzar a Espanya la primera insulina biosimilar de dispensaci\u00f3 a la farm\u00e0cia comunit\u00e0ria, la insulina glargina Abasaglar, nom comercial de la nova opci\u00f3 de tractament per als pacients amb diabetis tipus 1 i 2. Fabricada pels laboratoris Lilly i Boehringer Ingelheim, ha estat llen\u00e7ada al mercat espanyol com un biosimilar de la insulina Lantus del laboratori Sanofi. Es tracta de la primera insulina basal biosimilar del continent europeu.<\/p>\n<figure id=\"attachment_21406\" aria-describedby=\"caption-attachment-21406\" style=\"width: 227px\" class=\"wp-caption alignleft\"><a href=\"http:\/\/blog.cofb.cat\/wp-content\/uploads\/2016\/05\/biosimilars-COFB-mar\u00e7-2016-5.jpg\"><img decoding=\"async\" class=\" wp-image-21406 \" alt=\"biosimilars-COFB-mar\u00e7-2016 (5)\" src=\"http:\/\/blog.cofb.cat\/wp-content\/uploads\/2016\/05\/biosimilars-COFB-mar\u00e7-2016-5.jpg\" width=\"227\" height=\"340\" \/><\/a><figcaption id=\"caption-attachment-21406\" class=\"wp-caption-text\">Fernando de Mora (UAB)<\/figcaption><\/figure>\n<figure id=\"attachment_21403\" aria-describedby=\"caption-attachment-21403\" style=\"width: 357px\" class=\"wp-caption alignright\"><a href=\"http:\/\/blog.cofb.cat\/wp-content\/uploads\/2016\/05\/biosimilars-COFB-mar\u00e7-2016-2.jpg\"><img decoding=\"async\" class=\" wp-image-21403  \" alt=\"biosimilars-COFB-mar\u00e7-2016 (2)\" src=\"http:\/\/blog.cofb.cat\/wp-content\/uploads\/2016\/05\/biosimilars-COFB-mar\u00e7-2016-2.jpg\" width=\"357\" height=\"238\" \/><\/a><figcaption id=\"caption-attachment-21403\" class=\"wp-caption-text\">Xavier Cos (CAP Sant Mart\u00ed de Proven\u00e7als)<\/figcaption><\/figure>\n<p>Davant l\u2019arribada d\u2019aquest nou f\u00e0rmac, el COFB va acollir el 31 de mar\u00e7 una confer\u00e8ncia per informar els farmac\u00e8utics sobre les novetats que implica l&#8217;arribada de medicaments biosimilars a la farm\u00e0cia. <b>Fernando de Mora<\/b>, director del Departament de Farmacologia, de Terap\u00e8utica i de Toxicologia de la Facultat de Medicina de la Universitat Aut\u00f2noma de Barcelona, juntament amb <b>Xavier Cos<\/b>, metge de fam\u00edlia, director del CAP Sant Mart\u00ed de Proven\u00e7als (ICS) i Vice Chairman Primary Care Diabetes Europe, van ser els docents responsables de la formaci\u00f3.<\/p>\n<div class=\"box note\"><strong>Def. Biosimilars.\u00a0<\/strong>Es defineixen com aquells productes medicinals d\u2019origen biotecnol\u00f2gic similars a altres f\u00e0rmacs biol\u00f2gics innovadors, la patent dels quals ha expirat, produ\u00efts per un fabricant diferent, en noves l\u00ednies cel\u00b7lulars i nous processos. Es tracta aix\u00ed de medicaments similars, per\u00f2 no exactament id\u00e8ntics, als productes de refer\u00e8ncia, fins fa poc se\u2019ls anomenava tamb\u00e9 amb el terme biogen\u00e8rics per analogia amb els f\u00e0rmacs gen\u00e8rics de s\u00edntesi tradicionals.<\/p>\n<p>Font: \u201cMedicaments i farm\u00e0cia\u201d Canal Salut, Generalitat.<\/div>\n<p><strong>Per\u00f2 u<\/strong><strong>n medicament biosimilar no \u00e9s un medicament gen\u00e8ric,\u00a0<\/strong>ja que els medicaments biol\u00f2gics, com \u00e9s el cas de les insulines, estan\u00a0<strong>produ\u00efts per organismes vius manipulats gen\u00e8ticament,\u00a0<\/strong>\u00a0la qual cosa els distingeix dels medicaments de s\u00edntesi qu\u00edmica.\u00a0S\u00f3n mol\u00e8cules d\u2019estructura complexa i grans, \u00a0i en aquest cas,\u00a0els seus biosimilars no s\u00f3n una c\u00f2pia calcada de la mol\u00e8cula original sin\u00f3 estructures funcionalment bioequivalents, que han\u00a0demostrat que les lleus difer\u00e8ncies estructurals existents entre els dos productes inherents a la condici\u00f3 de biol\u00f2gic,\u00a0 no significa canvis en el seu comportament \u00a0farmacocin\u00e8tic, ni farmacodin\u00e0mic\u00a0i per tant que\u00a0\u00a0ofereix les mateixes garanties terap\u00e8utiques.<\/p>\n<figure id=\"attachment_21405\" aria-describedby=\"caption-attachment-21405\" style=\"width: 298px\" class=\"wp-caption alignleft\"><a href=\"http:\/\/blog.cofb.cat\/wp-content\/uploads\/2016\/05\/biosimilars-COFB-mar\u00e7-2016-4.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\" wp-image-21405  \" alt=\"biosimilars-COFB-mar\u00e7-2016 (4)\" src=\"http:\/\/blog.cofb.cat\/wp-content\/uploads\/2016\/05\/biosimilars-COFB-mar\u00e7-2016-4.jpg\" width=\"298\" height=\"199\" \/><\/a><figcaption id=\"caption-attachment-21405\" class=\"wp-caption-text\">Merc\u00e8 Barau (COFB)<\/figcaption><\/figure>\n<div class=\"box shadow\">\u201cEn principi els biosimilars, a difer\u00e8ncia dels gen\u00e8rics, <strong>no seran intercanviables ni podran substituir-se les prescripcions<\/strong>, encara que el metge s\u00ed que podr\u00e0 adequar la prescripci\u00f3 de medicaments, com la insulina o l&#8217;hormona de creixement, pel seu biosimilar\u201d explica <b>Merc\u00e8 Barau, vocal de la Junta de Govern del COFB i coordinadora<\/b> de l\u2019acte. \u201cAmb l\u2019experi\u00e8ncia que tenim a Europa, sembla que determinades mol\u00e8cules com \u00e9s el cas de la insulina, el seu biosimilar es podran autoritzar amb els estudis de farmacocin\u00e8tica i farmacodin\u00e0mica, ja que els estudis d\u2019efici\u00e8ncia i seguretat ja s\u2019han fet amb la mol\u00e8cula original\u201d. I matisa: \u201ca la confer\u00e8ncia tamb\u00e9 es va comentar que a les diferents comunitats aut\u00f2nomes<strong> no es canviaran tractaments per\u00f2 quan s\u2019hagin de comen\u00e7ar de nous es comen\u00e7ar\u00e0 el biosimilar<\/strong>\u201d.<\/div>\n<p><b>M\u00e9s informaci\u00f3:<\/b><\/p>\n<p><a href=\"http:\/\/www.ema.europa.eu\/docs\/es_ES\/document_library\/Medicine_QA\/2009\/12\/WC500020062.pdf\" target=\"_blank\" rel=\"noopener\">Preguntas y respuestas sobre medicamentos biosimilares (medicamentos biol\u00f3gicos similares) (via EMA \u2013 European Medicines Agency)<\/a><\/p>\n<p><a href=\"http:\/\/medicaments.gencat.cat\/ca\/professionals\/cedimcat\/documents-divulgatius-del-cedimcat\/medicaments-biotecnologics-i-biosimilars\/#FW_bloc_0b14e4a4-f7b0-11e3-8142-000c290c5684_3\" target=\"_blank\" rel=\"noopener\">Medicaments biotecnol\u00f2gics i biosimilars (via Canal Salut \u2013 Medicaments i Farm\u00e0cia, Gencat)<\/a><\/p>\n<p align=\"right\"><b>Amb la col\u00b7laboraci\u00f3 de: <\/b><\/p>\n<p align=\"right\">\u00a0<a href=\"http:\/\/www.lilly.es\/es\/index.aspx\" target=\"_blank\" rel=\"noopener\"><img loading=\"lazy\" decoding=\"async\" class=\" wp-image-11093 alignright\" alt=\"lilly\" src=\"http:\/\/blog.cofb.cat\/wp-content\/uploads\/2015\/01\/lilly.jpg\" width=\"117\" height=\"68\" \/><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>A finals del 2015 es va comercialitzar a Espanya la primera insulina biosimilar de dispensaci\u00f3 a la farm\u00e0cia comunit\u00e0ria, la insulina glargina Abasaglar, nom comercial de la nova opci\u00f3 de tractament per als pacients amb diabetis tipus 1 i 2. Fabricada pels laboratoris Lilly i Boehringer Ingelheim, ha estat llen\u00e7ada [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":21404,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_uag_custom_page_level_css":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"disabled","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[57],"tags":[64,2395,2396,2397,45],"class_list":["post-21391","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-mon-collegial","tag-atencio-farmaceutica","tag-biosimilar","tag-biosimilars","tag-insulina","tag-medicaments"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.4 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Els biosimilars arriben a la farm\u00e0cia, qu\u00e8 hem de saber? - Col\u00b7legi de Farmac\u00e8utics de Barcelona<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/novaorg.cofb.net\/2016\/05\/18\/els-biosimilars-arriben-a-la-farmacia-que-hem-de-saber\/\" \/>\n<meta property=\"og:locale\" content=\"ca_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Els biosimilars arriben a la farm\u00e0cia, qu\u00e8 hem de saber? - Col\u00b7legi de Farmac\u00e8utics de Barcelona\" \/>\n<meta property=\"og:description\" content=\"A finals del 2015 es va comercialitzar a Espanya la primera insulina biosimilar de dispensaci\u00f3 a la farm\u00e0cia comunit\u00e0ria, la insulina glargina Abasaglar, nom comercial de la nova opci\u00f3 de tractament per als pacients amb diabetis tipus 1 i 2. Fabricada pels laboratoris Lilly i Boehringer Ingelheim, ha estat llen\u00e7ada [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/novaorg.cofb.net\/2016\/05\/18\/els-biosimilars-arriben-a-la-farmacia-que-hem-de-saber\/\" \/>\n<meta property=\"og:site_name\" content=\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/farmaceuticsbcn\/\" \/>\n<meta property=\"article:published_time\" content=\"2016-05-18T10:44:09+00:00\" \/>\n<meta name=\"author\" content=\"wpAdminCofbOrg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@farmaceuticsbcn\" \/>\n<meta name=\"twitter:site\" content=\"@farmaceuticsbcn\" \/>\n<meta name=\"twitter:label1\" content=\"Escrit per\" \/>\n\t<meta name=\"twitter:data1\" content=\"wpAdminCofbOrg\" \/>\n\t<meta name=\"twitter:label2\" content=\"Temps estimat de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minuts\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/novaorg.cofb.net\/2016\/05\/18\/els-biosimilars-arriben-a-la-farmacia-que-hem-de-saber\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2016\/05\/18\/els-biosimilars-arriben-a-la-farmacia-que-hem-de-saber\/\"},\"author\":{\"name\":\"wpAdminCofbOrg\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb\"},\"headline\":\"Els biosimilars arriben a la farm\u00e0cia, qu\u00e8 hem de saber?\",\"datePublished\":\"2016-05-18T10:44:09+00:00\",\"dateModified\":\"2016-05-18T10:44:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2016\/05\/18\/els-biosimilars-arriben-a-la-farmacia-que-hem-de-saber\/\"},\"wordCount\":614,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.cofb.org\/#organization\"},\"image\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2016\/05\/18\/els-biosimilars-arriben-a-la-farmacia-que-hem-de-saber\/#primaryimage\"},\"thumbnailUrl\":\"\",\"keywords\":[\"Atenci\u00f3 farmac\u00e8utica\",\"biosimilar\",\"biosimilars\",\"insulina\",\"medicaments\"],\"articleSection\":[\"M\u00f3n col\u00b7legial\"],\"inLanguage\":\"ca\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/novaorg.cofb.net\/2016\/05\/18\/els-biosimilars-arriben-a-la-farmacia-que-hem-de-saber\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/novaorg.cofb.net\/2016\/05\/18\/els-biosimilars-arriben-a-la-farmacia-que-hem-de-saber\/\",\"url\":\"https:\/\/novaorg.cofb.net\/2016\/05\/18\/els-biosimilars-arriben-a-la-farmacia-que-hem-de-saber\/\",\"name\":\"Els biosimilars arriben a la farm\u00e0cia, qu\u00e8 hem de saber? - Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"isPartOf\":{\"@id\":\"https:\/\/www.cofb.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2016\/05\/18\/els-biosimilars-arriben-a-la-farmacia-que-hem-de-saber\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2016\/05\/18\/els-biosimilars-arriben-a-la-farmacia-que-hem-de-saber\/#primaryimage\"},\"thumbnailUrl\":\"\",\"datePublished\":\"2016-05-18T10:44:09+00:00\",\"dateModified\":\"2016-05-18T10:44:09+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2016\/05\/18\/els-biosimilars-arriben-a-la-farmacia-que-hem-de-saber\/#breadcrumb\"},\"inLanguage\":\"ca\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/novaorg.cofb.net\/2016\/05\/18\/els-biosimilars-arriben-a-la-farmacia-que-hem-de-saber\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/novaorg.cofb.net\/2016\/05\/18\/els-biosimilars-arriben-a-la-farmacia-que-hem-de-saber\/#primaryimage\",\"url\":\"\",\"contentUrl\":\"\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/novaorg.cofb.net\/2016\/05\/18\/els-biosimilars-arriben-a-la-farmacia-que-hem-de-saber\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Inici\",\"item\":\"https:\/\/novaorg.cofb.net\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Els biosimilars arriben a la farm\u00e0cia, qu\u00e8 hem de saber?\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.cofb.org\/#website\",\"url\":\"https:\/\/www.cofb.org\/\",\"name\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.cofb.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.cofb.org\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"ca\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.cofb.org\/#organization\",\"name\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"url\":\"https:\/\/www.cofb.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png\",\"contentUrl\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png\",\"width\":500,\"height\":105,\"caption\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\"},\"image\":{\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/farmaceuticsbcn\/\",\"https:\/\/twitter.com\/farmaceuticsbcn\",\"https:\/\/www.instagram.com\/farmaceuticsbcn\/\",\"https:\/\/www.linkedin.com\/company\/farmaceuticsbcn\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb\",\"name\":\"wpAdminCofbOrg\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g\",\"caption\":\"wpAdminCofbOrg\"},\"sameAs\":[\"http:\/\/192.168.64.122\/wordpress\"],\"url\":\"https:\/\/www.cofb.org\/ca\/author\/wpadmincofborg\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Els biosimilars arriben a la farm\u00e0cia, qu\u00e8 hem de saber? - Col\u00b7legi de Farmac\u00e8utics de Barcelona","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/novaorg.cofb.net\/2016\/05\/18\/els-biosimilars-arriben-a-la-farmacia-que-hem-de-saber\/","og_locale":"ca_ES","og_type":"article","og_title":"Els biosimilars arriben a la farm\u00e0cia, qu\u00e8 hem de saber? - Col\u00b7legi de Farmac\u00e8utics de Barcelona","og_description":"A finals del 2015 es va comercialitzar a Espanya la primera insulina biosimilar de dispensaci\u00f3 a la farm\u00e0cia comunit\u00e0ria, la insulina glargina Abasaglar, nom comercial de la nova opci\u00f3 de tractament per als pacients amb diabetis tipus 1 i 2. Fabricada pels laboratoris Lilly i Boehringer Ingelheim, ha estat llen\u00e7ada [&hellip;]","og_url":"https:\/\/novaorg.cofb.net\/2016\/05\/18\/els-biosimilars-arriben-a-la-farmacia-que-hem-de-saber\/","og_site_name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","article_publisher":"https:\/\/www.facebook.com\/farmaceuticsbcn\/","article_published_time":"2016-05-18T10:44:09+00:00","author":"wpAdminCofbOrg","twitter_card":"summary_large_image","twitter_creator":"@farmaceuticsbcn","twitter_site":"@farmaceuticsbcn","twitter_misc":{"Escrit per":"wpAdminCofbOrg","Temps estimat de lectura":"3 minuts"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/novaorg.cofb.net\/2016\/05\/18\/els-biosimilars-arriben-a-la-farmacia-que-hem-de-saber\/#article","isPartOf":{"@id":"https:\/\/novaorg.cofb.net\/2016\/05\/18\/els-biosimilars-arriben-a-la-farmacia-que-hem-de-saber\/"},"author":{"name":"wpAdminCofbOrg","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb"},"headline":"Els biosimilars arriben a la farm\u00e0cia, qu\u00e8 hem de saber?","datePublished":"2016-05-18T10:44:09+00:00","dateModified":"2016-05-18T10:44:09+00:00","mainEntityOfPage":{"@id":"https:\/\/novaorg.cofb.net\/2016\/05\/18\/els-biosimilars-arriben-a-la-farmacia-que-hem-de-saber\/"},"wordCount":614,"commentCount":0,"publisher":{"@id":"https:\/\/www.cofb.org\/#organization"},"image":{"@id":"https:\/\/novaorg.cofb.net\/2016\/05\/18\/els-biosimilars-arriben-a-la-farmacia-que-hem-de-saber\/#primaryimage"},"thumbnailUrl":"","keywords":["Atenci\u00f3 farmac\u00e8utica","biosimilar","biosimilars","insulina","medicaments"],"articleSection":["M\u00f3n col\u00b7legial"],"inLanguage":"ca","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/novaorg.cofb.net\/2016\/05\/18\/els-biosimilars-arriben-a-la-farmacia-que-hem-de-saber\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/novaorg.cofb.net\/2016\/05\/18\/els-biosimilars-arriben-a-la-farmacia-que-hem-de-saber\/","url":"https:\/\/novaorg.cofb.net\/2016\/05\/18\/els-biosimilars-arriben-a-la-farmacia-que-hem-de-saber\/","name":"Els biosimilars arriben a la farm\u00e0cia, qu\u00e8 hem de saber? - Col\u00b7legi de Farmac\u00e8utics de Barcelona","isPartOf":{"@id":"https:\/\/www.cofb.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/novaorg.cofb.net\/2016\/05\/18\/els-biosimilars-arriben-a-la-farmacia-que-hem-de-saber\/#primaryimage"},"image":{"@id":"https:\/\/novaorg.cofb.net\/2016\/05\/18\/els-biosimilars-arriben-a-la-farmacia-que-hem-de-saber\/#primaryimage"},"thumbnailUrl":"","datePublished":"2016-05-18T10:44:09+00:00","dateModified":"2016-05-18T10:44:09+00:00","breadcrumb":{"@id":"https:\/\/novaorg.cofb.net\/2016\/05\/18\/els-biosimilars-arriben-a-la-farmacia-que-hem-de-saber\/#breadcrumb"},"inLanguage":"ca","potentialAction":[{"@type":"ReadAction","target":["https:\/\/novaorg.cofb.net\/2016\/05\/18\/els-biosimilars-arriben-a-la-farmacia-que-hem-de-saber\/"]}]},{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/novaorg.cofb.net\/2016\/05\/18\/els-biosimilars-arriben-a-la-farmacia-que-hem-de-saber\/#primaryimage","url":"","contentUrl":""},{"@type":"BreadcrumbList","@id":"https:\/\/novaorg.cofb.net\/2016\/05\/18\/els-biosimilars-arriben-a-la-farmacia-que-hem-de-saber\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Inici","item":"https:\/\/novaorg.cofb.net\/"},{"@type":"ListItem","position":2,"name":"Els biosimilars arriben a la farm\u00e0cia, qu\u00e8 hem de saber?"}]},{"@type":"WebSite","@id":"https:\/\/www.cofb.org\/#website","url":"https:\/\/www.cofb.org\/","name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","description":"","publisher":{"@id":"https:\/\/www.cofb.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cofb.org\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"ca"},{"@type":"Organization","@id":"https:\/\/www.cofb.org\/#organization","name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","url":"https:\/\/www.cofb.org\/","logo":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/","url":"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png","contentUrl":"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png","width":500,"height":105,"caption":"Col\u00b7legi de Farmac\u00e8utics de Barcelona"},"image":{"@id":"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/farmaceuticsbcn\/","https:\/\/twitter.com\/farmaceuticsbcn","https:\/\/www.instagram.com\/farmaceuticsbcn\/","https:\/\/www.linkedin.com\/company\/farmaceuticsbcn\/"]},{"@type":"Person","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb","name":"wpAdminCofbOrg","image":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g","caption":"wpAdminCofbOrg"},"sameAs":["http:\/\/192.168.64.122\/wordpress"],"url":"https:\/\/www.cofb.org\/ca\/author\/wpadmincofborg\/"}]}},"uagb_featured_image_src":{"full":false,"thumbnail":false,"medium":false,"medium_large":false,"large":false,"1536x1536":false,"2048x2048":false,"trp-custom-language-flag":false},"uagb_author_info":{"display_name":"wpAdminCofbOrg","author_link":"https:\/\/www.cofb.org\/ca\/author\/wpadmincofborg\/"},"uagb_comment_info":0,"uagb_excerpt":"A finals del 2015 es va comercialitzar a Espanya la primera insulina biosimilar de dispensaci\u00f3 a la farm\u00e0cia comunit\u00e0ria, la insulina glargina Abasaglar, nom comercial de la nova opci\u00f3 de tractament per als pacients amb diabetis tipus 1 i 2. Fabricada pels laboratoris Lilly i Boehringer Ingelheim, ha estat llen\u00e7ada [&hellip;]","_links":{"self":[{"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/posts\/21391","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/comments?post=21391"}],"version-history":[{"count":0,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/posts\/21391\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/"}],"wp:attachment":[{"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/media?parent=21391"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/categories?post=21391"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/tags?post=21391"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}